Bristol Myers Squibb

BMS announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries.

Bristol Myers Squibb published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Bristol Myers Squibb (NYSE: BMY) unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Bristol Myers Squibb announced it has been recognized as One of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, recognized BMS for its commitment to key social responsibilities, including employees, customers, communities, and environmental impact.

This week, BMS announced a 15-year virtual power purchase agreement (VPPA) with National Grid Renewables for 145 megawatts (MW) of solar at the Texas-based Blevins Project. Combined with the 15-year VPPA with EDP Renewables secured in 2022, this move puts BMS another step closer.

Kareem Abdul-Jabbar is teaming up with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AFib) and its symptoms as part of the No Time to Wait campaign.

Hi, my name is Dana Walker. I’m the development program lead for genitourinary cancers here at Bristol Myers Squibb. I’m proud to lead a team of people continuing to develop treatments that help improve and extend the lives of patients dealing with genitourinary cancers.